scholarly journals Prospective study to validate clinical utility of DNA diagnosis of peritoneal fluid cytology test in gastric cancer

2021 ◽  
Author(s):  
Hiroki Harada ◽  
Takafumi Soeno ◽  
Nobuyuki Nishizawa ◽  
Marie Washio ◽  
Mikiko Sakuraya ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Prospective Study ◽  
Peritoneal Fluid ◽  
Clinical Utility ◽  
Dna Diagnosis ◽  
Fluid Cytology

scholarly journals DNA diagnosis of peritoneal fluid cytology test by CDO1 promoter DNA hypermethylation in gastric cancer

2017 ◽  
Vol 20 (5) ◽  
pp. 784-792 ◽  
Author(s):  
Hideki Ushiku ◽  
Keishi Yamashita ◽  
Akira Ema ◽  
Naoko Minatani ◽  
Mariko Kikuchi ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Peritoneal Fluid ◽  
Dna Hypermethylation ◽  
Dna Diagnosis ◽  
Promoter Dna ◽  
Fluid Cytology

Peritoneal fluid cytology predicts outcome in locally advanced gastric cancer

2000 ◽  
Vol 118 (4) ◽  
pp. A1050
Author(s):  
Martin R. Weiser ◽  
Patricia Saigo ◽  
Murray F. Brennan ◽  
Martin S. Karpeh
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Peritoneal Fluid ◽  
Locally Advanced ◽  
Locally Advanced Gastric Cancer ◽  
Fluid Cytology

scholarly journals UHPLC-ESI-MS/MS Quantification of Relevant Substrates and Metabolites of the Kynurenine Pathway Present in Serum and Peritoneal Fluid from Gastric Cancer Patients—Method Development and Validation

2021 ◽  
Vol 22 (13) ◽  
pp. 6972
Author(s):  
Ilona Sadok ◽  
Katarzyna Jędruchniewicz ◽  
Karol Rawicz-Pruszyński ◽  
Magdalena Staniszewska
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Peritoneal Fluid ◽  
Method Development ◽  
Solid Phase ◽  
Kynurenine Pathway ◽  
Serum Samples ◽  
Esi Ms ◽  
Gastric Cancer Patients ◽  
Development And Validation

Metabolites and enzymes involved in the kynurenine pathway (KP) are highly promising targets for cancer treatment, including gastrointestinal tract diseases. Thus, accurate quantification of these compounds in body fluids becomes increasingly important. The aim of this study was the development and validation of the UHPLC-ESI-MS/MS methods for targeted quantification of biologically important KP substrates (tryptophan and nicotinamide) and metabolites(kynurenines) in samples of serum and peritoneal fluid from gastric cancer patients. The serum samples were simply pretreated with trichloroacetic acid to precipitate proteins. The peritoneal fluid was purified by solid-phase extraction before analysis. Validation was carried out for both matrices independently. Analysis of the samples from gastric cancer patients showed different accumulations of tryptophan and its metabolites in different biofluids of the same patient. The protocols will be used for the evaluation of tryptophan and kynurenines in blood and peritoneal fluid to determine correlation with the clinicopathological status of gastric cancer or the disease’s prognosis.

scholarly journals Incomplete sulphomucin-secreting intestinal metaplasia for gastric cancer. Preliminary data from a prospective study from three centres.

Gut ◽  
1985 ◽  
Vol 26 (12) ◽  
pp. 1319-1326 ◽  
Author(s):  
M I Filipe ◽  
F Potet ◽  
W V Bogomoletz ◽  
P A Dawson ◽  
B Fabiani ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Prospective Study ◽  
Intestinal Metaplasia ◽  
Preliminary Data ◽  
A Prospective Study

A Prospective Study of Gastric Cancer

1998 ◽  
Vol 15 (4) ◽  
pp. 317-322 ◽  
Author(s):  
Gregorio F. Cenitagoya ◽  
Carlos K. Bergh ◽  
José Klinger-Roitman
Keyword(s):  
Gastric Cancer ◽  
Prospective Study ◽  
A Prospective Study

536 QUALITY OF LIFE AND FOLLOW-UP AFTER ESOPHAGEAL AND GASTRIC CANCER SURGERY. PROTOCOL FOR DEVELOPING AND TESTING A NEW FOLLOW-UP MODEL

2021 ◽  
Vol 34 (Supplement_1) ◽  
Author(s):  
I Hovdenak Jakobsen ◽  
D Kjaer
Keyword(s):  
Quality Of Life ◽  
Gastric Cancer ◽  
Adverse Effects ◽  
Prospective Study ◽  
Patient Involvement ◽  
Complex Interventions ◽  
National Implementation ◽  
Patient Reported

Abstract   Esophageal and gastric cancers are aggressive diseases. Due to extensive treatment, many patients experience adverse effects such as dysphagia, dumping, pain, fatigue, fear of recurrence and depression—all negatively impacting quality of life (QoL). The purpose of this study is to develop and test a follow-up model for patients after surgery for esophageal and gastric cancer. The model targets handling of adverse effects and psychosocial distress, aiming at improving patients’ QoL and functional level. Methods Development of the model follows recognized principles for complex interventions by the Medical Research Counsil. Extensive patient involvement is included in the development process, by means of a national patient advisory board. The assumed effect of the new model will be tested in a national two-part prospective study, executed before and after national implementation of the model, in both parts including approximately200 patients. Participants will be recruited prior to surgery, and follow-up is one year. Patient-reported data will be collected pre-operatively, at 3, 6, 9 and 12 months postoperatively, along with clinical and sociodemographic data. Results Development of the follow-up model after surgery will be completed in august 2020 and inclusion of patients for the prospective study part one, before implementation of the model, will commence summer 2020. Conclusion The perspectives of this study may be crucial for future follow-up of esophageal and gastric cancer patients. First, the extensive patient involvement in developing the model will ensure a patient-centred approach to follow-up. And second, the follow-up studies will provide important and up-to-date knowledge about clinical and patient-reported outcomes in a population-based, national cohort.

Sign in / Sign up

Export Citation Format

Share Document